Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin

Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines

(2012) Naoki Harada et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case–control study

(2011) Naoki Hiramatsu et al.   JOURNAL OF GASTROENTEROLOGY

Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

(2010) Yasuhiro Asahina et al.   HEPATOLOGY

Ageing, telomeres, senescence, and liver injury

(2010) Matthew Hoare et al.   JOURNAL OF HEPATOLOGY

Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France

(2009) Sylvie Deuffic-Burban et al.   HEPATOLOGY

Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

(2009) Mika Kurokawa et al.   HEPATOLOGY RESEARCH